Anne Brody Rubin

Perceive Biotherapeutics, Inc. is a biotech company that is focused on developing a diverse pipeline of targets and treatment modalities for various therapeutic verticals, with a particular emphasis on ophthalmology. The company is based in South San Francisco, CA. Perceive is backed by Deerfield Management and is planning to raise a series B later this year. The company was founded based on research that identified two novel protective biologies for treating retinal blindness, which were developed from collaborations in genetic science and target validation. Kristen Angela MacFarlane has been the CEO of the company since 2020.

ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ.

ForSight VISION4, Inc. develops novel drug delivery therapies for treatment of retinal diseases. The company was founded on June 26, 009 and is headquartered in Menlo Park, CA.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Medtronic Monitoring, Inc. treats cardiac arrhythmias. The company was founded in 2005 and is headquartered in San Jose, CA.